ReviewFrontiers in cell and developmental biology2025
Insights into O-GlcNAcylation and programmed cell death in cancer.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glutamine metabolism and its roles in tumor radiotherapy by regulating DNA damage repair.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
O-GlcNAcylation is an essential post-translational modification that adds O-linked β-N-acetylglucosamine (O-GlcNAc) to numerous proteins' serine or threonine residues. Several studies have indicated O-GlcNAcylation regulates various processes related to cancer, including signal transduction, transcription, cell division, metabolism, and cytoskeletal regulation. Programmed cell death (PCD) is a regulated and organized form of cell death controlled by genes, including apoptosis, autophagy, pyroptosis, necroptosis, and ferroptosis. As research on PCD has become increasingly in-depth, a potential link between O-GlcNAcylation and PCD has emerged. This review will focus on the complex relationships between O-GlcNAcylation and different PCD pathways, which are closely tied to the onset, progression, and resistance of cancer. By clarifying the relationship between O-GlcNAcylation and PCD, we aim to create a theoretical basis for improving anti-cancer treatments, with promising potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.